Further proof of the curative power of psilocybin:
Last year the
FDA in the USA helped to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder.
For the 2nd time in a year, the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy — currently being tested in clinical trials — as "breakthrough therapy",
an action that is meant to accelerate
"Breakthrough theapy" i
s typically granted by the FDA, only when preliminary research evidence suggests the drug may be an enormous
improvement over already available therapy.
Last year, the FDA had already granted "breakthrough therapy"
status to psilocybin therapy in the still-ongoing clinical trials run by the company called Compass Pathways.
The FDA were already looking into psilocybin's potential to treat severe treatment-resistant depression; or depression in patients who have not improved after undergoing two different antidepressant treatments, according to New Atlas.